Syros Pharmaceuticals, Inc. (SYRS)

Syros Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	85.64	141.65	170.55	95.39	177.07	41.73
Short-Term Investments	24.78	0	34.84	38.07	0	49.98
Cash & Cash Equivalents	110.42	141.65	205.39	133.46	177.07	91.71
Cash Growth	-34.62%	-31.04%	53.90%	-24.63%	93.08%	-8.58%
Receivables	0	0	1.69	0	0.01	20
Other Current Assets	1.78	3.34	4.31	3.13	1.48	2.81
Total Current Assets	112.2	144.98	211.39	136.59	178.56	114.51
Property, Plant & Equipment	18.86	19.48	24.66	27.29	29.64	31.89
Long-Term Investments	0	0	0	13.04	0	3.09
Other Long-Term Assets	3.67	3.71	8.43	6.03	5.05	0.49
Total Long-Term Assets	22.53	23.19	33.09	46.35	34.69	35.47
Total Assets	134.73	168.17	244.49	182.94	213.25	149.98
Accounts Payable	11.35	11.54	6.41	3.69	3.6	5.85
Deferred Revenue	0	0	4.33	10.18	22.09	28.38
Current Debt	14.08	8.99	2.07	2.01	1.73	1.28
Other Current Liabilities	11.88	16.15	17.97	15.62	1.21	-11.99
Total Current Liabilities	37.3	36.68	30.78	31.51	28.62	23.52
Long-Term Debt	47.6	53.08	61.5	63.18	64.49	24.64
Other Long-Term Liabilities	34.77	61.75	24.47	3.03	29.59	22.64
Total Long-Term Liabilities	82.37	114.83	85.97	66.21	94.07	47.28
Total Liabilities	119.67	151.51	116.75	97.72	122.7	70.79
Total Debt	61.67	62.08	63.57	65.19	66.21	25.92
Debt Growth	-2.38%	-2.35%	-2.49%	-1.54%	155.48%	83503.23%
Retained Earnings	-726.52	-722.81	-558.23	-463.58	-377.02	-292.98
Comprehensive Income	0	0	0.1	-0.08	0	0.02
Shareholders' Equity	15.06	16.66	127.74	85.22	90.55	79.18
Net Cash / Debt	48.75	79.57	141.82	68.26	110.86	65.79
Net Cash / Debt Growth	-53.88%	-43.89%	107.75%	-38.42%	68.50%	-34.40%
Net Cash Per Share	1.25	2.81	11.23	10.92	24.07	16.36
Working Capital	74.9	108.3	180.61	105.08	149.93	91
Book Value Per Share	0.39	0.59	10.11	13.63	19.66	19.69

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).